BCLI Plans Coming Together for Phase 3b Trial of NurOwn in ALS
BCLI Stock | USD 1.89 0.10 5.03% |
Under 61% of Brainstorm Cell's investor base is looking to short. The analysis of the overall investor sentiment regarding Brainstorm Cell Therapeutics suggests that many traders are alarmed. Brainstorm Cell's investing sentiment shows overall attitude of investors towards Brainstorm Cell Therapeutics.
Brainstorm |
By David Bautz, PhD NASDAQBCLI READ THE FULL BCLI RESEARCH REPORT Business Update Update on Planned Phase 3b Trial of NurOwn in ALS On December 30, 2024, BrainStorm Cell Therapeutics, Inc. conducted an investor update call to provide a corporate update. The company is currently preparing for a Phase 3b clinical trial of NurOwn in patients with amyotrophic lateral sclerosis .
Read at finance.yahoo.com
Brainstorm Cell Investor Sentiment by Other News Outlets
Investor sentiment, mood or attitude towards Brainstorm Cell can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Brainstorm Cell Fundamental Analysis
We analyze Brainstorm Cell's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Brainstorm Cell using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Brainstorm Cell based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Net Income
Net Income Comparative Analysis
Brainstorm Cell is currently under evaluation in net income category among its peers. Net income is the profit of a company for the reporting period, which is derived after taking revenues and gains and subtracting all expenses and losses. Net income is one of the most-watched numbers by money managers as well as individual investors.
Brainstorm Cell Ther Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Brainstorm Cell stock to make a market-neutral strategy. Peer analysis of Brainstorm Cell could also be used in its relative valuation, which is a method of valuing Brainstorm Cell by comparing valuation metrics with similar companies.
Peers
Brainstorm Cell Related Equities
XFOR | X4 Pharmaceuticals | 10.87 | ||||
GBIO | Generation Bio | 6.74 | ||||
CRVS | Corvus Pharmaceuticals | 5.92 | ||||
HCWB | HCW Biologics | 2.78 | ||||
CUE | Cue Biopharma | 2.34 | ||||
PLX | Protalix Biotherapeutics | 2.30 | ||||
BCAB | Bioatla | 2.08 | ||||
CCCC | C4 Therapeutics | 2.07 | ||||
PASG | Passage Bio | 1.69 | ||||
ANTX | AN2 Therapeutics | 1.60 | ||||
GRI | GRI Bio | 1.41 | ||||
ALDX | Aldeyra | 1.26 | ||||
DAWN | Day One | 1.13 | ||||
CNTB | Connect Biopharma | 0.96 | ||||
TRVI | Trevi Therapeutics | 0.53 | ||||
HOWL | Werewolf Therapeutics | 0.75 | ||||
MREO | Mereo BioPharma | 1.38 | ||||
INZY | Inozyme Pharma | 1.45 | ||||
TERN | Terns Pharmaceuticals | 1.56 | ||||
EWTX | Edgewise Therapeutics | 1.72 | ||||
CELC | Celcuity LLC | 2.84 | ||||
CKPT | Checkpoint Therapeutics | 4.50 |
Complementary Tools for Brainstorm Stock analysis
When running Brainstorm Cell's price analysis, check to measure Brainstorm Cell's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Brainstorm Cell is operating at the current time. Most of Brainstorm Cell's value examination focuses on studying past and present price action to predict the probability of Brainstorm Cell's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Brainstorm Cell's price. Additionally, you may evaluate how the addition of Brainstorm Cell to your portfolios can decrease your overall portfolio volatility.
Equity Valuation Check real value of public entities based on technical and fundamental data | |
Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges | |
Bonds Directory Find actively traded corporate debentures issued by US companies | |
Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital |